Treatment of post-transfusion graft-versus-host disease with nafmostat mesilate, a serine protease inhibitor

Background: Cytotoxic T lymphocytes from donors are thought to injure the target organs in post–transfusion graft–versus–host disease (PT–GVHD) through perforin–granzyme– and Fas–de